Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer

Overexpression of the EGFR ligands amphiregulin (AREG)/epiregulin (EREG) may be a surrogate of EGFR dependency regardless of sidedness in metastatic colorectal cancer. High AREG/EREG may be coupled with negative hyper-selection (i.e., lack of genomic drivers of primary resistance beyond RAS and BRAF...

Descripción completa

Detalles Bibliográficos
Autores principales: Randon, Giovanni, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
CCR Translations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570674/
https://www.ncbi.nlm.nih.gov/pubmed/37594733
http://dx.doi.org/10.1158/1078-0432.CCR-23-1954
_version_ 1785119821229195264
author Randon, Giovanni
Pietrantonio, Filippo
author_facet Randon, Giovanni
Pietrantonio, Filippo
author_sort Randon, Giovanni
collection PubMed
description Overexpression of the EGFR ligands amphiregulin (AREG)/epiregulin (EREG) may be a surrogate of EGFR dependency regardless of sidedness in metastatic colorectal cancer. High AREG/EREG may be coupled with negative hyper-selection (i.e., lack of genomic drivers of primary resistance beyond RAS and BRAF) to identify patients with right-sided tumors and potential sensitivity to EGFR blockade. See related article by Williams et al., p. 4153
format Online
Article
Text
id pubmed-10570674
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-105706742023-10-14 Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer Randon, Giovanni Pietrantonio, Filippo Clin Cancer Res CCR Translations Overexpression of the EGFR ligands amphiregulin (AREG)/epiregulin (EREG) may be a surrogate of EGFR dependency regardless of sidedness in metastatic colorectal cancer. High AREG/EREG may be coupled with negative hyper-selection (i.e., lack of genomic drivers of primary resistance beyond RAS and BRAF) to identify patients with right-sided tumors and potential sensitivity to EGFR blockade. See related article by Williams et al., p. 4153 American Association for Cancer Research 2023-10-13 2023-08-18 /pmc/articles/PMC10570674/ /pubmed/37594733 http://dx.doi.org/10.1158/1078-0432.CCR-23-1954 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle CCR Translations
Randon, Giovanni
Pietrantonio, Filippo
Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
title Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
title_full Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
title_fullStr Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
title_full_unstemmed Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
title_short Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
title_sort towards multiomics-based dissection of anti-egfr sensitivity in colorectal cancer
topic CCR Translations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570674/
https://www.ncbi.nlm.nih.gov/pubmed/37594733
http://dx.doi.org/10.1158/1078-0432.CCR-23-1954
work_keys_str_mv AT randongiovanni towardsmultiomicsbaseddissectionofantiegfrsensitivityincolorectalcancer
AT pietrantoniofilippo towardsmultiomicsbaseddissectionofantiegfrsensitivityincolorectalcancer

Ejemplares similares